United States Securities and Exchange Commission · EDGAR Accession 0001949139-26-000004

Form C-AR

Annual Report — Regulation Crowdfunding
Issuer CIK 1949139
Period 2025-12-31

Diant Pharma Inc.

CorporationDEIncorporated 2019Manchester, CTdiantpharma.com
B

Financial Condition

two fiscal years, as filed
Revenue +80% YoYBurn increasingDebt / assets 27%9 employees
Line itemMost recent FYPrior FYΔ
Revenue1,530,991849,070▲ 80%
Cost of goods sold881,307279,180▲ 216%
Net income(538,167)(414,051)▼ burn
Total assets1,690,0321,766,948▼ 4%
Cash & equivalents29,33055,455▼ 47%
Accounts receivable103,2760
Short-term debt265,049104,358▲ 154%
Long-term debt190,4060
Taxes paid15,29212,727▲ 20%

Figures in USD as reported by the issuer.